ResMed (RMD) PT Lowered to $255 at Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $240.41 +5.87%
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Mizuho analyst Anthony Petrone lowered the price target on ResMed (NYSE: RMD) to $255.00 (from $300.00) while maintaining a Outperform rating.
You May Also Be Interested In
- AMD (AMD) PT Raised to $600 at DA Davidson
- SGHC Limited (SGHC) PT Lowered to $16 at StoneX
- Canaccord Downgrades ResMed (RMD:AU) (RMD) to Hold
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
